BTCY · XBRL financial data

Biotricity financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BTCY's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Revenue from contracts with customers	3,385	7,650	9,639	12,063	13,790	15,998
Cost of revenue	1,871	3,080	4,197	3,707	3,226	3,049
Gross profit	1,514	4,570	5,442	8,356	10,564	12,949
Research and development	2,059	2,745	3,230	2,572	2,156	2,764
Selling, general and administrative	—	18,562	17,622	14,613	10,858	8,493
General and administrative	12,806	19,846	—	—	—	—
Total operating expenses	14,865	22,591	20,852	17,185	13,013	11,258
Operating income (loss)	—	(16,737)	(15,410)	(8,828)	(2,449)	1,691
Interest expense	—	380	1,839	3,019	3,262	3,362
Other income (expense)	(37)	15	(111)	(103)	(79)	160
Net income (loss)	(15,491)	(29,130)	(18,658)	(14,094)	(8,421)	(2,404)
Earnings per share, basic USD per share	(0.44)	(0.67)	(0.38)	(1.66)	(0.56)	(0.12)
Earnings per share, diluted USD per share	—	—	(2.26)	(1.66)	(0.56)	(0.12)
Weighted average shares, basic thousands of shares	37,523	45,450	51,958	8,992	21,525	27,304
Weighted average shares, diluted thousands of shares	—	—	8,660	8,992	21,525	27,304

Fiscal years (BTCY's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Cash and cash equivalents	2,202	12,067	570	786	365	150
Accounts receivable	1,521	2,007	1,224	1,469	1,659	2,933
Inventory	272	843	2,337	1,879	1,555	1,341
Total current assets	4,322	15,323	4,720	4,471	4,639	5,856
Property and equipment, net	—	27	22	16	10	4
Right-of-use asset	66	1,243	1,587	1,222	812	346
Total assets	4,438	16,678	6,511	5,943	5,641	6,446
Accounts payable	1,041	—	—	—	—	—
Accrued liabilities	1,479	1,436	1,607	4,370	3,034	4,535
Total current liabilities	10,490	4,867	11,161	22,699	20,636	37,141
Lease liability, non-current	—	1,120	1,386	929	398	—
Total liabilities	11,271	18,823	26,356	35,919	35,655	39,409
Accumulated deficit	(62,818)	(93,037)	(112,571)	(127,500)	(139,442)	(142,570)
Total stockholders' equity	(6,833)	(2,145)	(19,845)	(31,466)	(32,014)	(34,677)
Total liabilities and equity	4,438	16,678	6,511	5,943	5,641	6,446
Common shares outstanding (cover page) thousands of shares	37,850	50,302	51,048	21,484	26,568	20,075

Fiscal years (BTCY's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Net income (loss)	(15,491)	(29,130)	(18,658)	(14,094)	(8,421)	(2,404)
Stock-based compensation	791	914	648	1,026	1,462	26
Net cash from operating activities	(11,081)	(15,163)	(13,548)	(6,694)	(2,380)	(719)
Purchases of property and equipment	—	30	—	—	—	—
Net cash from investing activities	—	(30)	—	—	—	—
Proceeds from issuing common stock	—	250	—	119	125	—
Dividends paid	603	—	—	—	—	—
Net cash from financing activities	12,203	25,168	2,002	6,742	1,929	558
Net change in cash	1,191	—	—	48	(451)	—

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Biotricity	467	4,277	507	19.9M	—	Q1 FY27 10-QJun 30, 2026
VASO	38,291	not reported	17,444*	176.0M	—	Q2 FY26 10-QJun 30, 2026
Iridex	4,680	12,566	174*	17.6M	—	Q2 FY26 10-QJul 4, 2026
Envoy Medical	19,679	51	(5,456)*	77.2M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Nexalin Technology	1,005	12	(1,802)*	22.0M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
PetVivo Holdings	123	338	(966)	38.0M	0.1 quarters	Q1 FY27 10-QJun 30, 2026
PAVmed	3,784	33	(2,663)*	8.0M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Beyond Air	5,509	1,768	(4,946)	957,631	2.0 quarters	Q1 FY27 10-QJun 30, 2026
RetinalGenix Technologies	27	not reported	(137)*	18.8M	0.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.